The shareholder vote removes a key condition to closing. Focus now shifts to regulatory approvals, particularly HSR and non-U.S. antitrust clearances. Monitor for updates on these fronts; any delay or condition could affect the timeline. The expected close in H2 2026 remains intact per Boston Scientific's Q1 call.
Price Chart
Executive Summary
Penumbra shareholders voted overwhelmingly to approve the merger with Boston Scientific, with 99.7% of votes cast in favor. The deal now awaits remaining regulatory clearances (HSR and foreign antitrust) and is expected to close in the second half of 2026.
Key Financial Metrics
Key Facts
- 28,564,786 votes FOR the merger (99.7% of cast votes), 85,334 AGAINST, 15,813 abstentions
- 28,665,933 shares present or proxy out of 39,324,084 outstanding (72.9% quorum)
- Advisory compensation proposal also approved (27,811,605 FOR)
- Merger agreement dated January 14, 2026; Penumbra to survive as wholly owned subsidiary of Boston Scientific
- Remaining conditions: HSR waiting period expiration/termination and non-U.S. antitrust/foreign investment clearances
Financial Impact
No financial figures disclosed in this filing; deal value and terms are in prior merger agreement filings.
Risk Factors
- Failure to obtain remaining regulatory approvals (HSR, foreign antitrust/investment clearances)
- Potential for regulatory conditions that could alter deal terms or timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001321732-26-000025 |
| Document: 0001321732-26-000025-index-headers.html | 0001321732-26-000025 |
| Document: 0001321732-26-000025-index.html | 0001321732-26-000025 |
| Document: 0001321732-26-000025.txt | 0001321732-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | Press Release | $321.19 $321.68 | ▼ −0.15% | ▲ +2.84% | $317.55 (+1.13%) |
May 7, 2026 21w ago | 425 | $324.65 $319.37 | ▼ −1.63% | ▼ −4.76% | $317.55 (−2.19%) |
May 6, 2026 21w ago | 8-K | $324.65 $319.37 | ▲ +1.63% | ▲ +4.76% | $317.55 (+2.19%) |
Apr 29, 2026 22w ago | DEFA14A | $326.48 $318.30 | ▼ −2.51% | ▼ −7.73% | $317.55 (−2.74%) |
Apr 17, 2026 24w ago | 425 | $329.71 $326.54 | ▼ −0.96% | ▼ −5.16% | $317.55 (−3.69%) |
Apr 1, 2026 26w ago | DEFM14A | $330.36 $326.48 | ▼ −1.17% | ▼ −11.05% | $317.55 (−3.88%) |
Feb 25, 2026 31w ago | 8-K | $338.67 $336.27 | ▼ −0.71% | ▲ +4.53% | $317.55 (−6.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access